FrancophonIA/ELRC3.0 huggingface dataset:
English: In order to improve the traceability of this medicine, your doctor or pharmacist should record the tradename and the lot number of the product you have been given in your patient file.
Slovenian: Za izboljšanje sledljivosti tega zdravila morata zdravnik ali farmacevt v bolnikovi dokumentaciji zabeležiti trgovsko ime in serijsko številko zdravila, ki ste ga prejeli.
English: 95% CI for one sample binomial using Pearson-Clopper method.
Slovenian: 95-% interval zaupanja (IZ) za binomski test enega vzorca z uporabo Pearson-Clopperjeve metode.
English: Efficacy results for trial E4599
Slovenian: Rezultati učinkovitosti za preskušanje E4599
English: Hypertensive encephalopathya
Slovenian: hipertenzivna encefalopatijac
English: • an abnormal tube-like connection or passage between the windpipe and the gullet, between internal organs and skin, between the vagina and any parts of the gut or between other tissues that are not normally connected (fistula), and are judged by your doctor to be severe,
Slovenian: • neobičajna povezava ali prehod, podoben cevi, med sapnikom in požiralnikom, med notranjimi organi in kožo, med nožnico in katerim koli delom črevesa ali med drugimi tkivi, ki normalno niso povezani (fistula), in jih vaš zdravnik oceni kot resne,
English: Do not use this medicine after the expiry date which is stated on the outer carton and on the vial label after the abbreviation EXP.
Slovenian: Tega zdravila ne smete uporabljajti po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepki viale poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
English: Depending on the dose prescribed for you, some or all of the contents of the MVASI vial will be diluted with sodium chloride solution before use.
Slovenian: Odvisno od odmerka, ki vam ga je predpisal zdravnik, je treba del ali vso vsebino viale zdravila MVASI pred uporabo razredčiti z raztopino natrijevega klorida.
English: No adverse events leading to death occurred in either treatment arm; all deaths were attributed to disease progression.
Slovenian: V nobeni od zdravljenih skupin ni bilo neželenih učinkov, ki bi bili smrtni; vsi smrtni primeri so bili zaradi napredovanja bolezni.
English: MVASI contains the active substance bevacizumab, which is a humanised monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer).
Slovenian: Zdravilo MVASI vsebuje zdravilno učinkovino bevacizumab, ki je humanizirano monoklonsko protitelo (vrsta beljakovine, ki jo običajno proizvaja imunski sistem, da pomaga telesu pri obrambi proti okužbam in raku).
English: % patients with objective response p-value
Slovenian: % bolnic z objektivnim odgovorom p-vrednost
English: MVASI is contraindicated in pregnancy (see section 4.3).
Slovenian: Zdravilo MVASI je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
English: The overall safety profile of bevacizumab is based on data from over 5,700 patients with various malignancies, predominantly treated with bevacizumab in combination with chemotherapy in clinical trials.
Slovenian: Celotni varnostni profil bevacizumaba temelji na podatkih več kot 5700 bolnikov z različnimi malignimi boleznimi, ki so se v kliničnih preskušanjih večinoma zdravili z bevacizumabom v kombinaciji s kemoterapijo.
English: The population pharmacokinetics were analysed in adult and paediatric patients to evaluate the effects of demographic characteristics.
Slovenian: Pri odraslih in pediatričnih bolnikih so z analizo populacijske farmakokinetike proučili vpliv demografskih značilnosti na farmakokinetiko.
English: Please let your doctor, pharmacist or nurse know if you have previously experienced problems after injections, such as dizziness/feeling of fainting, breathlessness, swelling or skin rash.
Slovenian: Svojega zdravnika, farmacevta ali medicinsko sestro obvestite, če ste že imeli težave po injiciranju, kot je omotica/občutek slabotnosti, težave pri dihanju (zasoplost), otekanje ali kožni izpuščaj.
English: This is consistent with results in patients in other studies of metastatic breast cancer who did not receive concurrent anthracycline treatment (NCI-CTCAE v.3) (see section 4.8).
Slovenian: To je skladno z rezultati pri bolnikih v drugih preskušanjih pri metastatskemu raku dojk, ki niso prejemali sočasnega zdravljenja z antraciklini (NCICTCAE v.3) (glejte poglavje 4.8).
English: PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion.
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje.
English: Efficacy results1,2 from study GOG-0213
Slovenian: Rezultati učinkovitosti1,2 iz študije GOG-0213
English: Tables 1 and 2 list adverse reactions associated with the use of bevacizumab in combination with different chemotherapy regimens in multiple indications.
Slovenian: V preglednicah 1 in 2 so našteti neželeni učinki, ki so povezani z uporabo bevacizumaba v kombinaciji z različnimi shemami kemoterapije pri več indikacijah.
English: Hypertension was generally adequately controlled with oral anti-hypertensives such as angiotensinconverting enzyme inhibitors, diuretics and calcium-channel blockers.
Slovenian: Hipertenzija je bila v večini primerov ustrezno uravnana s peroralnimi antihipertenzivi, kot so zaviralci angiotenzinske konvertaze, diuretiki in blokatorji kalcijevih kanalčkov.
English: Patients should have had a life expectancy of ≥ 12 weeks and no prior radiotherapy to the pelvis or abdomen.
Slovenian: Bolnice so morale imeti pričakovano preživetje ≥ 12 tednov in v preteklosti niso smele prejeti radioterapije medenice ali trebuha.
English: An increased incidence of post-operative bleeding or wound healing complication occurring within 60 days of major surgery was observed if the patient was being treated with bevacizumab at the time of surgery.
Slovenian: Povečano incidenco za pooperativno krvavitev ali zaplet pri celjenju ran, ki se pojavi v 60 dneh po večji operaciji, so opazili v primerih, ko se je bolnik v času operacije zdravil z bevacizumabom.
English: The analysis of the primary endpoint showed no difference between the bevacizumab + placebo arm and the bevacizumab + erlotinib arm (median PFS 8.5 versus 9.9 months).
Slovenian: Analiza primarnega cilja raziskave ni pokazala razlik med skupino z bevacizumabom + placebom in skupino z bevacizumabom + erlotinibom (mediana preživetja brez napredovanja bolezni 8,5 v primerjavi z 9,9 meseca).
English: MVASI should be permanently discontinued if medically significant hypertension cannot be adequately controlled with antihypertensive therapy, or if the patient develops hypertensive crisis or hypertensive encephalopathy.
Slovenian: Zdravilo MVASI dokončno opustimo, če klinično pomembne hipertenzije ni mogoče ustrezno uravnati z antihipertenzivnimi zdravili ali če se je pri bolniku pojavila hipertenzivna kriza ali hipertenzivna encefalopatija.
English: The typical value for central volume (Vc) was 2.73 L and 3.28 L for female and male patients respectively, which is in the range that has been described for IgGs and other monoclonal antibodies.
Slovenian: Tipična vrednost za volumen osrednjega prostora (Vc) je bila 2,73 l pri bolnicah in 3,28 l pri bolnikih, kar je v območju, ki so ga opisali za imunoglobuline G in druga monoklonska protitelesa.
English: Bevacizumab in combination with interferon alfa-2a for the first-line treatment of advanced and/ or metastatic renal cell cancer (BO17705)
Slovenian: Bevacizumab v kombinaciji z interferonom alfa 2-a v prvi liniji zdravljenja napredovalega in/ali metastatskega raka ledvičnih celic (BO17705)
English: In terms of safety, there was a higher overall incidence of grade 3-5 AEs in study E3200 relative to study ML18147.
Slovenian: Kar se tiče varnosti, je bila v študiji E3200 celokupno večja incidenca neželenih dogodkov stopnje 3-5 glede na študijo ML18147.
English: In adults the results showed no significant difference in the pharmacokinetics of bevacizumab in relation to age.
Slovenian: Rezultati so pokazali, da pri odraslih ni značilnih razlik v farmakokinetiki bevacuzimaba glede na starost.
English: • bleeding, including bleeding in the lungs in patients with non-small cell lung cancer,
Slovenian: • krvavitev, vključno s krvavitvijo v pljučih pri bolnikih z nedrobnoceličnim rakom pljuč,
English: • dry skin, flaking and inflammation of the skin, change in skin colour,
Slovenian: • suho kožo, luskavost in vnetje kože, spremembo barve kože,
English: • Redness of the eye, small particles or spots in your vision (floaters), eye pain,
Slovenian: • pordelost očesa, majhni delci ali madeži v vidnem polju (motnjave), bolečina v očesu,
English: IFN alfa-2a was given up to 52 weeks or until disease progression at a recommended starting dose of 9 MIU three times a week, allowing a dose reduction to 3 MIU three times a week in 2 steps.
Slovenian: Interferon alfa-2a so prejemali do 52 tednov ali do napredovanja bolezni, priporočeni začetni odmerek je bil 9 mio i.e. trikrat na teden, dovoljeno pa ga je bilo zmanjšati v dveh korakih na 3 mio i.e. trikrat na teden.
English: You must not use this medicine if you are pregnant.
Slovenian: Če ste noseči, tega zdravila ne smete prejemati.
English: The concentrate is a clear to slightly opalescent, colourless to slightly yellow liquid in a glass vial with a rubber stopper.
Slovenian: Koncentrat je bistro do rahlo opalescentna, brezbarvna do rahlo rumena tekočina v stekleni viali z gumijastim zamaškom.
English: Patients should be monitored for signs and symptoms of CNS bleeding, and MVASI treatment discontinued in cases of intracranial bleeding.
Slovenian: Bolnike je treba spremljati za znake ali simptome krvavitev v osrednjem živčevju in zdravljenje z zdravilom MVASI v primerih intrakranialne krvavitve prekiniti.
English: If you stop treatment with MVASI
Slovenian: Če ste prenehali jemati zdravilo MVASI
English: 5 mg/kg IV 30-90 min Day 1, prior to FOLFOX-4, every 2 weeks
Slovenian: 30-90 min 1. dan, pred FOLFOX-4, vsaka 2 tedna
English: Trial results show that 94% (277 / 296) of eligible patients went on to receive single agent bevacizumab at cycle 7.
Slovenian: Rezultati preskušanja kažejo, da je 94 % (277/296) primernih bolnikov s 7. ciklom nadaljevalo s samostojnim zdravljenjem z bevacizumabom.
English: Overall approximately 34% of patients were FIGO stage III optimally debulked with gross residual disease, 40% stage III suboptimally debulked, and 26% were stage IV patients.
Slovenian: Celokupno je približno 34 % bolnic imelo po FIGO klasifikaciji bolezen stadija III, z opravljeno optimalno citoredukcijo, s preostankom bolezni; 40 % jih je imelo bolezen stadija III, z opravljeno suboptimalno citoredukcijo in 26 % je imelo bolezen stadija IV.
English: In the majority of the occasions the necessary amount of MVASI can be diluted with 0.9% sodium chloride solution for injection to a total volume of 100 mL.
Slovenian: V večini primerov lahko potrebno količino zdravila MVASI razredčimo z 0,9-% raztopino natrijevega klorida za injiciranje do končnega volumna 100 ml.
English: The pharmacokinetics of bevacizumab were evaluated in 152 children, adolescents and young adults (7 months to 21 years, 5.9 to 125 kg) across 4 clinical studies in paediatrics using a population pharmacokinetic model.
Slovenian: Farmakokinetiko bevacizumaba so ocenili pri 152 otrocih, mladostnikih in mlajših odraslih (7 mesecev do 21 let; 5,9 do 125 kg) v 4 kliničnih študijah pri pediatrični populaciji z uporabo populacijskega farmakokinetičnega modela.
English: Statistically significant improvements in progression-free survival and objective response rate were also observed (see table 8).
Slovenian: Opazili so tudi statistično značilna izboljšanja v preživetju brez napredovanja bolezni in objektivnem odgovoru na zdravljenje (glejte preglednico 8).
English: Bevacizumab use has been associated with serious cases of fistulae including reactions resulting in death.
Slovenian: Uporaba bevacizumaba je bila povezana z resnimi primeri fistul, vključno s takimi, ki so se končali s smrtjo.
English: • MVASI can increase the incidence of high blood pressure.
Slovenian: • zdravilo MVASI lahko poveča pojavnost visokega krvnega tlaka.
English: The efficacy results of bevacizumab in combination with IFL-chemotherapy are displayed in table 4.
Slovenian: Rezultate učinkovitosti bevacizumaba v kombinaciji z IFL-kemoterapijo prikazuje preglednica 4.
English: • fistula: abnormal tube-like connection between internal organs and skin or other tissues that are not normally connected, including connections between vagina and the gut in patients with cervical cancer.
Slovenian: • fistule: nenormalne cevaste povezave med notranjimi organi in kožo ali drugimi tkivi, ki normalno niso povezani, med drugim povezave med nožnico in črevesom pri bolnicah z rakom materničnega vratu.
English: MVASI is also used for the treatment of adult patients with advanced non-small cell lung cancer when cancer cells have specific mutations of a protein called epidermal growth factor receptor (EGFR).
Slovenian: Zdravilo MVASI uporabljamo tudi za zdravljenje odraslih bolnikov z napredovalim nedrobnoceličnim rakom pljuč, ko imajo rakave celice določene mutacije beljakovine, ki se imenuje receptor epidermalnega rastnega faktorja (EGFR).
English: Secondary PFS analyses, based on ‘on-treatment'-based response assessments, confirmed the significantly superior clinical benefit for patients treated with bevacizumab (analyses shown in table 7), consistent with the statistically significant benefit observed in the pooled analysis.
Slovenian: Sekundarne analize preživetja brez napredovanja bolezni, ki so temeljile na ocenah odgovora ob zdravljenju (′on-treatment′), so potrdile signifikantno superiorno klinično korist za bolnike, ki so jih zdravili z bevacizumabom (analiza prikazana v preglednici 7), kar je v skladu s statistično signifikantno koristjo, ki so jo opazili v združenih analizah podatkov.
English: Overall survival6
Slovenian: Celokupno preživetje6
English: • localised pus collection,
Slovenian: • lokalizirano nabiranje gnoja,
English: In most clinical trials urine protein levels of ≥ 2g/24 hrs led to stopping treatment with bevacizumab until recovery to < 2g/24 hrs.
Slovenian: V večini kliničnih preskušanj so koncentracije beljakovin v seču ≥ 2 g/24 ur povzročile prekinitev zdravljenja z bevacizumabom, dokler ni prišlo do zmanjšanja < 2 g/24 ur.
English: Bevacizumab 10 mg/kg was given every 2 weeks until disease progression.
Slovenian: Bevacizumab so prejemali v odmerku 10 mg/kg vsaka dva tedna do napredovanja bolezni.
English: Most patients were FIGO stage IIIC or stage IV.
Slovenian: Večina bolnic je imela stadij IIIC ali IV po klasifikaciji FIGO.
English: Efficacy results for study ML18147 (ITT population)
Slovenian: Rezultati učinkovitosti za študijo ML18147 (populacija bolnikov, ki so jo nameravali zdraviti)
English: Efficacy results for trial BO17705
Slovenian: Rezultati učinkovitosti preskušanja BO17705
English: Fistulae have also been reported in post-marketing experience.
Slovenian: O fistulah so poročali tudi v obdobju po prihodu zdravila na trg.
English: If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Slovenian: Hranjenje navadno ne sme biti daljše od 24 ur pri temperaturi 2 °C do 8°C, razen če je bila raztopina pripravljena v kontroliranih in validiranih aseptičnih pogojih.
English: The efficacy data from trials AVF0780g and AVF2192g investigating bevacizumab in combination with 5-FU/FA chemotherapy are summarised in table 5.
Slovenian: Podatki o učinkovitosti iz preskušanj AVF0780g in AVF2192g, ki sta proučevali bevacizumab v kombinaciji s kemoterapevtsko shemo 5-FU/FA, so povzeti v preglednici 5.
English: • increase in heart rate (pulse),
Slovenian: • povišanje frekvence bitja srca (utripa),
English: Caution should be taken when treating these patients with MVASI.
Slovenian: Pri zdravljenju teh bolnikov z zdravilom MVASI je zato potrebna previdnost.
English: The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/mL (0.9%) solution for injection.
Slovenian: Potrebno količino bevacizumaba je potrebno odvzeti in jo razredčiti do ustreznega volumna za aplikacijo z 9 mg/ml (0,9-%) raztopino natrijevega klorida za injiciranje.
English: These therapies in combination with MVASI may increase the risk of severe side effects.
Slovenian: Ta zdravila lahko v kombinaciji z zdravilom MVASI povečajo tveganje za pojav hudih neželenih učinkov.
English: Do not use MVASI if you notice any particulate matter or discolouration prior to administration.
Slovenian: Ne uporabljajte zdravila MVASI, če opazite kakršne koli delce ali obarvanje pred dajanjem.
English: • shortness of breath or low levels of oxygen in the blood,
Slovenian: • zasoplost ali nizko vsebnost kisika v krvi,
English: • It is possible that MVASI may cause bleeding in and around your brain.
Slovenian: • možno je, da lahko zdravilo MVASI povzroči krvavitve v možganih in okoli možganov.
English: The primary endpoint was PFS based on investigator's assessment of disease progression based on radiological scans or CA-125 levels, or symptomatic deterioration per protocol.
Slovenian: Primarni cilj študije je bil preživetje brez napredovanja bolezni, ki temelji na oceni raziskovalca o napredovanju bolezni glede na radiološki posnetek ali določitvi vrednosti CA 125 oziroma na simptomatsko poslabšanje glede na protokol.
English: Studies in animals have shown reproductive toxicity including malformations (see section 5.3).
Slovenian: Študije na živalih so pokazale škodljiv vpliv na sposobnost razmnoževanja, vključno z malformacijami (glejte poglavje 5.3).
English: • Pregnancy (see section 4.6).
Slovenian: • Nosečnost (glejte poglavje 4.6).
English: A high proportion of patients (approximately 63% IFN/placebo; 55% bevacizumab/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Slovenian: Visok delež bolnikov (približno 63 % interferon/placebo; 55 % bevacizumab/placebo) je po zaključku študije prejemal različna nespecificirana zdravljenja novotvorb, vključno z antineoplastičnimi zdravili, kar je lahko imelo vpliv na analizo celokupnega preživetja.
English: Efficacy results from study AVF4095g
Slovenian: Rezultati učinkovitosti iz študije AVF4095g
English: Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No (Yes = randomised to undergo cytoreduction or randomised to not undergo cytoreduction; No = not a candidate or did not consent to cytoreduction).
Slovenian: Razmerje ogroženosti so ocenili iz Coxovih modelov sorazmernih ogroženosti, stratificiranih s trajanjem intervala brez platine pred vključitvijo v to študijo glede na elektronski obrazec za poročanje o primerih (eCRF, electronic case report form) in sekundarno s statusom kirurške odstranitve Da/Ne (Da = randomizirane, da bodo imele citoredukcijo ali randomizirane, da citoredukcije ne bodo imele; Ne = ni bila kandidatka za citoredukcijo ali z njo ni soglašala).
English: The pharmacokinetics of bevacizumab was well characterised by the paediatric population PK model for 70 paediatric patients in study BO20924 (1.4 to 17.6 years; 11.6 to 77.5 kg) and 59 patients in study BO25041 (1 to 17 years; 11.2 to 82.3 kg).
Slovenian: Farmakokinetika bevacizumaba je bila dobro opredeljena z uporabo farmakokinetičnega modela pediatrične populacije za 70 pediatričnih bolnikov iz študije BO20924 (1,4 do 17,6 let; 11,6 do 77,5 kg) in za 59 bolnikov iz študije BO25041 (1 do 17 let; 11,2 do 82,3 kg).
English: • reduced blood supply to the brain or stroke,
Slovenian: • zmanjšan dotok krvi v možgane ali kap,
English: In most clinical trials of bevacizumab, patients with pre-existing CHF of NYHA (New York Heart Association) II-IV were excluded, therefore, no information is available on the risk of CHF in this population.
Slovenian: V večino kliničnih preskušanj z bevacizumabom bolniki, ki so imeli kongestivno srčno popuščanje pred pričetkom zdravljenja (NYHA - New York Heart Association II−IV), niso bili vključeni, zato informacije o tveganju za kongestivno srčno popuščanje pri tej populaciji niso na voljo.
English: In Part II, treatment assignment was double-blind with respect to bevacizumab.
Slovenian: delu je bila določitev zdravljenja glede uporabe bevacizumaba dvojno slepa.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 25 mg of bevacizumab*.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml koncentrata vsebuje 25 mg bevacizumaba*.
English: In clinical trials of metastatic carcinoma of the colon or rectum, there was no increased risk of postoperative bleeding or wound healing complications observed in patients who underwent major surgery 28-60 days prior to starting bevacizumab.
Slovenian: V kliničnih preskušanjih metastatskega raka debelega črevesa in danke ni bilo povečanega tveganja za pooperativno krvavitev ali zaplete pri celjenju ran pri bolnikih, ki so imeli večjo operacijo 28 do 60 dni pred začetkom zdravljenja z bevacizumabom.
English: Infections and infestations Necrotising fasciitis, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation (rare) (see also section 4.4)
Slovenian: Infekcijske in parazitske bolezni nekrotizirajoči fasciitis, ponavadi sekundaren zapletom pri celjenju ran, perforaciji prebavil ali nastanku fistule (redko) (glejte tudi poglavje 4.4)
English: Combination with platinum- or taxane-based therapies (see sections 4.4 and 4.8)
Slovenian: Kombinacija z zdravljenjem na osnovi platine ali taksanov (glejte poglavji 4.4 in 4.8)
English: The concentration of the final bevacizumab solution should be kept within the range of 1.4 mg/mL to 16.5 mg/mL.
Slovenian: Koncentracija končne raztopine bevacizumaba mora biti od 1,4 do 16,5 mg/ml.
English: Overall survival3
Slovenian: Celokupno preživetje3
English: • serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing,
Slovenian: • resne okužbe kože ali globljih plasti pod kožo, še posebno, če ste imeli luknje v črevesni steni ali težave pri celjenju ran,
English: Arm 1
Slovenian: Skupina 1
English: Combination of bevacizumab and sunitinib malate
Slovenian: Kombinacija bevacizumaba in sunitinibijevega malata
English: Patients with non-small cell lung cancer treated with bevacizumab may be at risk of serious, and in some cases fatal, pulmonary haemorrhage/haemoptysis.
Slovenian: Pri bolnikih z nedrobnoceličnim rakom pljuč, ki se zdravijo z bevacizumabom, lahko obstaja tveganje za resno in v nekaterih primerih smrtno krvavitev v pljučih/hemoptizo.
English: • feeling of numbness or tingling in hands or feet,
Slovenian: • občutek otrplosti ali zbadanja v dlaneh ali nogah,
English: MVASI infusions should not be administered or mixed with glucose solutions.
Slovenian: Infuzije zdravila MVASI se ne sme dajati ali mešati skupaj z raztopinami glukoze.
English: The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and adult patients when normalised by body weight, with exposure trending lower as body weight decreased.
Slovenian: Farmakokinetični rezultati kažejo, da sta bila po normiranju glede na telesno maso očistek in volumen porazdelitve bevacizumaba med pediatričnimi in odraslimi bolniki primerljiva, z izpostavljenostjo, ki se je z manjšanjem telesne mase zmanjševala.
English: • It is possible that MVASI can increase the risk of bleeding in your lungs, including coughing or spitting blood.
Slovenian: • možno je, da lahko zdravilo MVASI poveča tveganje za krvavitve v pljučih, vključno s kašljanjem in izpljuvanjem krvi.
English: 0.80 (p = 0.003) 95% CI (0.69; 0.93)
Slovenian: 0,80 (p = 0,003) 95-% interval zaupanja (0,69; 0,93)